The European Medicines Agency (EMA)’s guidelines on conflicts of interest disclosure for patient and consumer groups are an essential tool to evaluate real or perceived conflicts of interest with the pharmaceutical industry. Research from Corporate Europe Observatory has however found that the administration of the guidelines has failed to stop missing or misleading statements from several patient groups which have denied being sponsored by industry,
Five years ago the European Transparency Initiative was launched. This book highlights what has been achieved since then and what ground is left to cover.
Quito, 21st April. Various experts and civil society organisation that came together in a meeting of the Latin American and Caribe and European Alliance for Access to Medicines, positively evaluated the recent measures taken by the Ecuadorian government, through the application of a compulsory license on Kaletra® , (lopinavi/ritonavir) medicines of the treatment of HIV/AIDs.
On April 21, 2010, an official version of the consolidated negotiating text of the proposal Anti-Counterfeiting Trade Agreement (ACTA) was published. Next Wednesday, April 28, 2010, the Trans-Atlantic Consumer Dialogue (TACD) will host a series of roundtable discussions about the new ACTA text at the US Department of commerce, Washington, DC from 9am to 3pm.
The Association of the British Pharmaceutical Industry (ABPI) has lost a legal battle against schemes promoted by Britain’s state health service that encourage doctors to prescribe cheaper medicines.
The European Court of Justice has decided that public authorities may offer financial incentives to induce doctors to prescribe cheaper medicinal products. And that such incentives are not to be considered advertising,
Conflict of interest disclosure is essential if transparency is to be achieved.
Yet, recent research from Corporate Europe Observatory has revealed loopholes at the European Medicines Agency. The forms used to declare competing interests do not seem to be consistently interpreted by patient and consumer experts, generating some intriguing cases…
For more information,
Today, the draft negotiating text for the Anti-Counterfeiting Trade Agreement (ACTA) was published. However, for those finding it difficult to locate the draft text document, please find the link below:
and, the link to the Joint Statement on ACTA:
The Global Health Communication that came out on April 1st contains some good language on Innovation & Access. However it also contains an worrying reference to IMPACT in the policy coherece, trade and access to medicines section. It is interesting this reference has found its way into this section of the EU Global Health Commmunication just now that IMPACT is under heavy fire at the WHO,
Andrew Tolve writes that patient groups are yet another means to provide the education and support needed to boost adherance. The full article is reported by Eye for Pharma on 9 Mar 2010.
Non-adherence is a serious financial concern. John Hosken of Eye for Pharma estimates that
“…drug companies are losing around 25 billlion euros each year simply through patients not taking their medicine.”
Finnish researchers E. Hemminki, H.K. Toiviainen, and L. Vuorenkoski reported that drug companies see patient group sponsorship as a means to inform patients about their products and to move their medicines to a more favourable reimbursement class.
The full article, titled Co-operation between patient organisations and the drug industry in Finland,